ME02844B - Verbindungen und zusammensetzungen zur modulation der egfr-aktivität - Google Patents
Verbindungen und zusammensetzungen zur modulation der egfr-aktivitätInfo
- Publication number
- ME02844B ME02844B MEP-2017-232A MEP2017232A ME02844B ME 02844 B ME02844 B ME 02844B ME P2017232 A MEP2017232 A ME P2017232A ME 02844 B ME02844 B ME 02844B
- Authority
- ME
- Montenegro
- Prior art keywords
- enoil
- benzodiazol
- metil
- azepan
- carboksamid
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 37
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 title 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 title 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 88
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 37
- 229910052739 hydrogen Inorganic materials 0.000 claims 27
- 239000001257 hydrogen Substances 0.000 claims 27
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 23
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 20
- 125000005842 heteroatom Chemical group 0.000 claims 20
- 229910052760 oxygen Inorganic materials 0.000 claims 20
- 229910052717 sulfur Inorganic materials 0.000 claims 20
- 150000002431 hydrogen Chemical class 0.000 claims 14
- 125000005843 halogen group Chemical group 0.000 claims 13
- -1 (4-acetylpiperazin-1-yl)methyl Chemical group 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000004043 oxo group Chemical group O=* 0.000 claims 9
- 102000001301 EGF receptor Human genes 0.000 claims 8
- 108060006698 EGF receptor Proteins 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000003368 amide group Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 7
- 229910052698 phosphorus Inorganic materials 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 5
- 125000002950 monocyclic group Chemical group 0.000 claims 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 125000005936 piperidyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- UVNXNSUKKOLFBM-UHFFFAOYSA-N imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=CSC2=NC=CN21 UVNXNSUKKOLFBM-UHFFFAOYSA-N 0.000 claims 1
- 150000002460 imidazoles Chemical group 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims 1
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- XILZLQGBIXBPPH-WUTDNEBXSA-N n-[1-[(3r)-1-[(e)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methylbenzimidazol-2-yl]-2-(trifluoromethyl)pyridine-4-carboxamide Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(C)C=CC=C2N=C1NC(=O)C1=CC=NC(C(F)(F)F)=C1 XILZLQGBIXBPPH-WUTDNEBXSA-N 0.000 claims 1
- GJGPWVYIYZTHOA-ICKBMGCOSA-N n-[7-chloro-1-[(3r)-1-[(e)-4-pyrrolidin-1-ylbut-2-enoyl]azepan-3-yl]benzimidazol-2-yl]-2-methylpyridine-4-carboxamide Chemical compound C1=NC(C)=CC(C(=O)NC=2N(C3=C(Cl)C=CC=C3N=2)[C@H]2CN(CCCC2)C(=O)\C=C\CN2CCCC2)=C1 GJGPWVYIYZTHOA-ICKBMGCOSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 102200048955 rs121434569 Human genes 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
Landscapes
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2012DE1741 | 2012-06-06 | ||
| US201361770752P | 2013-02-28 | 2013-02-28 | |
| PCT/US2013/044247 WO2013184757A1 (en) | 2012-06-06 | 2013-06-05 | Compounds and compositions for modulating egfr activity |
| EP13729219.9A EP2773635B1 (de) | 2012-06-06 | 2013-06-05 | Verbindungen und zusammensetzungen zur modulation der egfr-aktivität |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02844B true ME02844B (de) | 2018-01-20 |
Family
ID=62200061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-232A ME02844B (de) | 2012-06-06 | 2013-06-05 | Verbindungen und zusammensetzungen zur modulation der egfr-aktivität |
Country Status (1)
| Country | Link |
|---|---|
| ME (1) | ME02844B (de) |
-
2013
- 2013-06-05 ME MEP-2017-232A patent/ME02844B/de unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171670T1 (hr) | Spojevi i sastavi za moduliranje egfr-aktiviteta | |
| ES2962852T3 (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de los mismos | |
| ES2904252T3 (es) | Moduladores de CCR2 | |
| ES2989326T3 (es) | Compuestos de benzolactama como inhibidores de la proteína cinasa | |
| RU2326881C9 (ru) | Конденсированные производные азолпиримидина, обладающие свойствами ингибитора фосфатидилинозитол-3-киназы (pi3k) | |
| AU679045B2 (en) | Benzimidazole derivatives | |
| ES2834462T3 (es) | Compuestos heterocíclicos bicíclicos y sus usos en terapia | |
| ES2898835T3 (es) | Azol amidas y aminas como inhibidores de la integrina alfav | |
| JP2014516074A5 (de) | ||
| ES2852351T3 (es) | Pirrolamidas como inhibidores de la integrina alfa V | |
| JP2019508384A (ja) | ５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン | |
| HRP20201469T1 (hr) | Derivati tetrahidroizokinolina | |
| ES2319642T3 (es) | Derivados 1,4-di-piperidina-4-il-piperazina sustituidos y su uso como antagonistas de la neuroquinina. | |
| BR112019012957A2 (pt) | derivados de tetra-hidroimidazo[4,5-c]piridina como indutores de internalização de pd-l1 | |
| BR112020008839A2 (pt) | moduladores da via de estresse integrada | |
| JP2019519586A5 (de) | ||
| JP2011520832A5 (de) | ||
| JP2006503010A5 (de) | ||
| WO2009065919A2 (de) | Organische verbindungen | |
| CA2853390A1 (en) | Anticancer pyridopyrazines via the inhibition of fgfr kinases | |
| HRP20120457T1 (hr) | 4-(4-cijano-2-tioaril)dihidropirimidinoni i njihova uporaba | |
| JP2013539777A5 (de) | ||
| JP2015529192A5 (de) | ||
| BR112020003594A2 (pt) | derivados de benzimidazol como antagonistas de receptor de adenosina | |
| KR20180013850A (ko) | 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도 |